Teaser: Off-label systemic agents may treat inflammatory autoimmune vulvar diseases such as lichen sclerosus and lichen ...

DEBRA Research and LEO Pharma enter strategic partnership to advance treatments for rare skin diseases: Munich, Germany Thursday, February 6, 2025, 10:00 Hrs [IST] DEBRA Research ...

German non-profit organization DEBRA Research GmbH, supporting those affected by epidermolysis bullosa (EB), and Denmark’s LEO Pharma announced a non-exclusive strategic partnership.

Junshi Biosciences and TopAlliance are set to enter a collaboration with LEO Pharma to distribute and market toripalimab in ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Major deals, including Johnson & Johnson’s $14.6B Intra-Cellular acquisition, signal renewed dealmaking, supported by nearly ...

Jan 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory ...

A class action settlement has been reached in Stewart v. LEO Pharma Inc. et al, S.C.B.C. No. S2010053 (the "Claim").

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of ...

Gilead will pay LEO Pharma $250 million upfront under the arrangement; further milestone payments may boost the total to $1.7 billion. While LEO Pharma maintains worldwide rights to topical ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...